Dear All: As you know if you are a regular reader of this newsletter, I think that creation of suitable Pull incentives by passage of the PASTEUR Act in the United States is key to building a vibrant pipeline of products to address the international problem of AMR. I’ve also written recently about the FORWARD Act
Dear All, Excitingly, NIAID has released a new BAA (Broad Agency Announcement) entitled “Diagnostics Pre-Clinical Services Program.” Similar to the prior BAA for support of biopharmaceutical product development, this new BAA for diagnostic devices seeks a group who can manage a “multiple award Indefinite Delivery/Indefinite Quantity (IDIQ) type contract” (read that slowly!) and through it offer a comprehensive
Dear All (lots and lots of wonkish detail here, be sure your blood caffeine level is adequate!), During the 24-28 Aug 2020 BEAM Alliance-sponsored AMR Conference (go here or see below my signature for more), I had the opportunity on 27 August to chat with Sumati Nambiar (FDA) and Marco Cavaleri (EMA) about ongoing regulatory activities. The
Note: Since sending the 18 May 2024 newsletter about the new WHO bacterial PPL, I have learned of a 2021 PPL from Japan! Please see the Bugs & Drugs webpage to get an updated .pptx or .pdf summarizing all 8 PPLs published to date.Dear All (wonkish alert … but definitely worth the effort! Refill your coffee!),Ramanan Laxminarayan and about
Dear All, Today is a newsletter double-header! Coming hard on the heels of the opportunity to support an ESCMID petition to UNGA 2024, the UK today released the details of its next five-year action plan. Excitingly for this audience, there is an updated roadmap for the UK’s next steps in its subscription model. Here are
Dear All, During the GLG AMR (Global Leaders Group for AMR) event just before ECCMID (see the 3 May 2024 newsletter entitled “Path To UNGA 2024 As Of 3 May 24 / Events On 14-15 May (DC, NYC)” for details), ESCMID leadership announced that ESCMID had developed a petition to be sent by and from the
Dear All, Well, ECCMID 2024 (Barcelona) has come and gone. I saw many of you there … but it’s always so busy … and the conference center was simply enormous! Could not keep up. But, it was great to get the sense that we’re back as a community … very good attendance. The one thing
Dear All (moderately wonkish, so settle in for the ride — and the reason for the title of this newsletter will become obvious!), The GLG AMR (Global Leaders Group on Antimicrobial Resistance) released a report on 3 April 2024 providing recommendations for consideration by UN Member States in the outcome document of the High-Level Meeting (HLM) on
Dear All, If you follow US politics, you will know that the USG (US Government) is beginning its appropriations process for FY2025 (Federal Year 2025). In preparation, a letter calling for AMR-related funding has been drafted by the Infectious Diseases Society of America (IDSA), AdvaMedDx, American Society for Microbiology (ASM), Association for Professionals in Infection Control
Dear All, To end the week, we have a really lovely paper from the Swiss Roundtable on Antibiotics (a multidisciplinary, non-profit Swiss association). Here are the links you need: The new (25 March 2024) paper entitled “Effective antibiotics for the Swiss health care system: today and in the future.” A prior (7 Feb 2023) paper
Using ideas to connect, create, and inspire
Supported by the Wellcome Trust